首页 | 本学科首页   官方微博 | 高级检索  
检索        

个体化静脉营养治疗对不能进食晚期肿瘤患者疗效的回顾性分析
引用本文:于雷,潘新刚,丛明华,李宁,宋晨鑫,何慧丽.个体化静脉营养治疗对不能进食晚期肿瘤患者疗效的回顾性分析[J].医学综述,2013(21):3997-3999.
作者姓名:于雷  潘新刚  丛明华  李宁  宋晨鑫  何慧丽
作者单位:[1]中国医学科学院肿瘤医院综合科,北京100021 [2]山东省文登市中心医院消化内科,威海264400 [3]北京武警总医院药剂科,北京100039
摘    要:目的研究个体化静脉营养治疗对晚期不能进食肿瘤患者生存期的影响。方法选取2009年3月至2012年10月于中国医学科学院肿瘤医院综合科住院的40例不能进食晚期肿瘤患者为研究对象,其中营养支持组20例:接受个体化静脉营养治疗联合减症支持治疗;减症组20例:接受减症支持治疗。分析、比较两组生存期及治疗一个月后部分血生化指标。结果营养支持组平均生存时间为(176.7±24.0).d,减症组平均生存时间为(58.2±15.4)d,营养支持组平均生存时间较减症组显著延长(P〈0.01),营养支持组6例患者死于恶病质,减症组13倒死于恶病质,营养支持组显著少于减症组(P〈0.05)。营养支持组一个月后体质量指数、白蛋白及淋巴细胞计数均较治疗前显著升高l(18.53±0.91)kg/m^2vs(17.83±0.75)kg/m^2、(31.31±2.88)g/Lvs(27.354-2.67)g/L、(1.78±0.40)g/L vs(1.29±0.18)g/L,P〈0.01],而减症组一个月后体质量指数、白蛋白及淋巴细胞计数均较治疗前显著降低(17.14±1.58)kg/m^2 (18.88±1.23)kg/In2、(24.88±3.58)g/Lvs(26.99±2.79)g/L、(1.09±0.25)g/Lvs(1.49±0.23)g/L,P〈0.01)]。结论个体化静脉营兼治疗可以显著征长不能进食晚期肿瘤患者生存时间及降低恶病质死因。

关 键 词:全胃肠外营养  个体化  癌症  恶病质  生存期

Retrospective Analysis of Therapeutic Effect of Individualized TPN Treatment on Advanced Stage Cancer Patients
YU Lei,PAN Xin-gang,CONG Ming-hua,LINing,SONG Chen-xin,HE Hui-li.Retrospective Analysis of Therapeutic Effect of Individualized TPN Treatment on Advanced Stage Cancer Patients[J].Medical Recapitulate,2013(21):3997-3999.
Authors:YU Lei  PAN Xin-gang  CONG Ming-hua  LINing  SONG Chen-xin  HE Hui-li
Institution:. ( 1. General Medicine Department, Cancer Hospital of Chinelse Academy of Medical Science, Belting 100021 , China; 2. Digestive Medicine Department, Central Hospital of Wendeng City, Weihai 264400, China; 3. Department of Pharmacy, General Hospital of Armed Police Force ,Belting 100039, China )
Abstract:Objective To evaluate therapeutic effect on survival time of individualized TPN treatment on advanced stage cancer patients. Methods Forty advanced stage cancer patients adopted in Cancer Hospital of Chinese Academy of Medical Science from Mar. 2009 to Oct. 2012 were analyzed with retrospective cohort methods. Two cohorts were analyzed, one with 20 patients who received individualized TPN treatment and supportive care, while the other with 20 patients received supportive care without TPN. Survival time and sev- eral blood biochemistry markers were compared between the cohorts. Results The average survival time of patients with TPN treatment was (176.7 + 24.0 ) days, longer significantly than the other cohort, which was (58.2 + 15.4 )days. (P 〈 0.01 ). 6 pafients died from caehexia in TPN cohort, significantly less than the other cohort,which was 13 (P〈 0.05 ). BMI, ALB and LYM levels were significantly increased after one month treatment with TPN(18.53 ±0.91)kg/m^2 vs (17.83 ±0.75)kg/m^2,(31,31 ±2.88) g/L vs (27.35±2.67 ) g/L, ( 1.78± 0.40 ) g/L vs ( 1.29 ± 0. 18 ) g/L, P 〈 0.01 ] , while decreased after one month treatment with supportive care ( 17.14 ± 1.58) kg/m^2 vs ( 18.88 ± 1.23 ) kg/m^2, (24.88 ±3.58) g/L vs (26.99 ±2.79) g/L,(1.09±0.25) g/Lvs(1.49±0.23) g/L,P〈0.01].Conclusion Individualized TPN treatment can prolong the smwival time of advanced stage caneer patients,and reduce the cause of dying from caehexia.
Keywords:Total parenteral nutrition  Individualization  Cancer  Cachexia  Survival time
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号